CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Favipiravir PlaceboWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (4)

Name (Synonyms) Correlation
drug528 Carrimycin Wiki 1.00
drug2873 lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate Wiki 1.00
drug2753 basic treatment Wiki 0.71
drug923 Favipiravir Wiki 0.24

Correlated MeSH Terms (3)

Name (Synonyms) Correlation
D003141 Communicable Diseases NIH 0.09
D007239 Infection NIH 0.06
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Control of COVID-19 Outbreaks in Long Term Care (CONTROL-COVID)

To address the need to intervene to prevent the spread of COVID-19 in long-term care homes, we propose a randomized clinical trial of chemoprophylaxis in long-term care homes experiencing COVID-19 outbreaks. LTCH units experiencing an outbreak of COVID-19 will be randomized to chemoprophylaxis with favipiravir or placebo in a 1:1 ratio. Chemoprophylaxis in this setting refers to the use of favipiravir for pre-exposure prophylaxis, post-exposure prophylaxis, pre-emptive therapy, or treatment for established COVID-19. This design mimics the approach to influenza outbreaks, which has proven efficacy for outbreak control. The primary outcome will be control of the outbreak, defined as no new microbiologically confirmed case of COVID-19 for 24 consecutive days up to day 40.

NCT04448119 COVID-19 SARS-CoV-2 Drug: Favipiravir Drug: Favipiravir Placebo

Primary Outcomes

Description: Control of outbreak, defined as no new cases of COVID-19 in residents for 24 consecutive days up to day 40 after the start of prophylaxis

Measure: Control of Outbreak

Time: Day 40

Secondary Outcomes

Description: The proportion of residents of included LTCH units who die up to day 40, and up to day 60

Measure: Mortality (Residents)

Time: Day 40, Day 60

Description: The proportion of residents of included LTCH units who were uninfected at baseline and develop new symptomatic microbiologically confirmed COVID-19 up to day 40

Measure: COVID-19 Infection (Residents)

Time: Day 40

Description: The proportion of exposed staff uninfected at baseline in whom SARS-CoV-2 infection is identified up to day 14 and up to day 40

Measure: COVID-19 Infection (Staff)

Time: Day 14, Day 40

Description: The proportion of residents of included LTCH units hospitalized up to day 40

Measure: Hospitalization (Residents)

Time: Day 40

Description: The proportion of residents of included LTCH units who discontinue study medication due to adverse events

Measure: Medication Discontinuation (Residents)

Time: Day 40

Description: The proportion of LTCH staff of included LTCH units who discontinue study medication due to adverse events

Measure: Medication Discontinuation (Staff)

Time: Day 40

Description: The occurrence of new microbiologically confirmed COVID-19 infections in residents in other units of the LTCH up to day 40 (dichotomous, at LTCH level)

Measure: COVID-19 in new LTCH Units (a)

Time: Day 40

Description: The proportion of previously unaffected LTCH units of the remainder of the LTCH in which a case of COVID-19 is identified

Measure: COVID-19 in new LTCH Units (b)

Time: Day 40

Description: The proportion of residents in the remainder of the LTCH who develop COVID-19 infections up to day 40

Measure: COVID-19 in new LTCH Units (c)

Time: Day 40

No related HPO nodes (Using clinical trials)